Dyne Therapeutics (DYN) announced the appointment of Erick Lucera as CFO of Dyne, effective March 31. Lucera brings more than thirty years of financial, operational and investment experience in the life science industry to Dyne. Lucera joins Dyne from Editas Medicine (EDIT).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
- Buy Rating Affirmed for Dyne Therapeutics Amid Promising DYNE-251 Data and Strategic Milestones
- Promising Advancements and Strategic Positioning of Dyne Therapeutics’ DYNE-251: A Buy Rating Analysis
- Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251
- Dyne Therapeutics: Innovative Approaches and Promising Clinical Programs Drive Buy Rating